Scientific article
Open access

Management of hepatitis C virus (HCV) infection in drug substitution programs

Published inSchweizerische medizinische Wochenschrift, vol. 141, w13193
Publication date2011

In Switzerland, intravenous drug use (IDU) accounts for 80% of newly acquired hepatitis C virus (HCV) infections. Early HCV treatment has the potential to interrupt the transmission chain and reduce morbidity/mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programs are often insufficiently screened and treated.

  • Adult
  • Antiviral Agents/therapeutic use
  • Cross-Sectional Studies
  • Delayed Diagnosis/statistics & numerical data
  • Female
  • Genotype
  • HIV Infections/complications
  • Hepacivirus/genetics
  • Hepatitis C/complications/diagnosis/drug therapy/virology
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance/statistics & numerical data
  • RNA, Viral/blood
  • Retrospective Studies
  • Substance Abuse Treatment Centers/statistics & numerical data
  • Substance-Related Disorders/complications
  • Switzerland
  • Time Factors
  • Young Adult
Citation (ISO format)
WITTECK, Andrea et al. Management of hepatitis C virus (HCV) infection in drug substitution programs. In: Schweizerische medizinische Wochenschrift, 2011, vol. 141, p. w13193. doi: 10.4414/smw.2011.13193
Main files (1)
Article (Published version)
ISSN of the journal0036-7672

Technical informations

Creation10/24/2012 3:33:00 PM
First validation10/24/2012 3:33:00 PM
Update time03/14/2023 5:49:17 PM
Status update03/14/2023 5:49:16 PM
Last indexation08/29/2023 5:28:05 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack